Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the fourth quarter and fiscal year (FY) ended April 30, 2017, and provided an update on its …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of promising new data from its Phase III SUNRISE trial of bavituximab in patients with previously treated …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the third quarter of fiscal year (FY) 2017 ended January 31, 2017, and provided an update …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform. Results of the study, conducted at University …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the second quarter of fiscal year (FY) 2017 ended October 31, 2016, and provided an update …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of positive data from multiple new preclinical studies of the company’s phosphatidylserine (PS)-targeting antibodies. Study results highlight …
Peregrine Pharmaceuticals (NASDAQ:PPHM) reported that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or …
Yesterday, Peregrine Pharmaceuticals (NASDAQ:PPHM) hosted a conference call to discuss its financial first quarter results for 2017, with the three-month quarter having ended …
